AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
263.30B
Market cap263.30B
Price-Earnings ratio
31.21
Price-Earnings ratio31.21
Dividend yield
1.83%
Dividend yield1.83%
Average volume
4.46M
Average volume4.46M
High today
$85.15
High today$85.15
Low today
$84.23
Low today$84.23
Open price
$84.53
Open price$84.53
Volume
4.11M
Volume4.11M
52 Week high
$86.57
52 Week high$86.57
52 Week low
$61.24
52 Week low$61.24

Stock Snapshot

AstraZeneca(AZN) stock is priced at $84.29, giving the company a market capitalization of 263.3B. It carries a P/E multiple of 31.21 and pays a dividend yield of 1.8%.

On 2025-11-07, AstraZeneca(AZN) stock traded between a low of $84.23 and a high of $85.15. Shares are currently priced at $84.29, which is +0.1% above the low and -1.0% below the high.

AstraZeneca(AZN) shares are trading with a volume of 4.11M, against a daily average of 4.46M.

During the past year, AstraZeneca(AZN) stock moved between $61.24 at its lowest and $86.57 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $61.24 at its lowest and $86.57 at its peak.

AZN News

TipRanks 7h
Midday Fly By: Musk pay plan approved, ‘GTA VI’ delayed

The major averages were broadly lower near noon, putting the biggest indices on track for a down week. Stocks tied to artificial intelligence and semiconductors...

TipRanks 9h
AstraZeneca CEO warns U.K. faces generics-only future, Guardian reports

AstraZeneca (AZN) CEO Pascal Soriot has warned that if the U.K. does not increase spending on new drugs, it could eventually be limited to only affordable gener...

TipRanks 10h
AstraZeneca reports statistical significance in NATRON trial

Full results from the NATRON Phase III trial showed AstraZeneca’s (AZN) Fasenra demonstrated a statistically significant delay in the time to first worsening or...

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
15.6%
Sell
3.1%

More AZN News

TipRanks 19h
AstraZeneca Reports Strong Growth and Pipeline Success

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. Meet Your ETF AI Analyst Di...

The Motley Fool 1d
Why AstraZeneca Stock Topped the Market on Thursday

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter. Veteran pharmaceutical company AstraZeneca (AZN +3.23%) delivered...

Why AstraZeneca Stock Topped the Market on Thursday
Benzinga 1d
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the con...

AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable
Investor's Business Daily 1d
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar

AstraZeneca (AZN) stock popped early Thursday after the pharma company reported earnings of $2.38 per share on $15.19 billion in third-quarter sales. On averag...

AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar
TipRanks 2d
AstraZeneca reports Q3 core EPS $2.38, up 12% at CER

Reports Q3 revenue $15.2B, consensus $15.36B. Pascal Soriot, Chief Executive Officer, AstraZeneca (AZN), commenting on the results said: “The strong underlying...

Nasdaq 2d
European Shares Mostly Lower Ahead Of BoE Rate Decision

(RTTNews) - European stocks drifted lower on Thursday despite a broad market recovery in the U.S. and in overnight trade in Asia. Regional losses remained limi...

European Shares Mostly Lower Ahead Of BoE Rate Decision
Nasdaq 2d
AstraZeneca Q3 Results Climb, Top Estimate; Backs FY25 Outlook

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) reported Thursday significantly higher profit in its third quarter with good growth in revenues. Co...

AstraZeneca Q3 Results Climb, Top Estimate; Backs FY25 Outlook
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.